Differential insulin-like growth factor II (IGF-II) expression: A potential role for breast cancer survival disparity

Growth Hormone and IGF Research

Volumn 20, Issue 2, 2010, Pages 162-170

  Kalla Singh, S ^a   Tan, Q W ^a   Brito, C ^a   De Leon M ^a   Garberoglio, C ^a   De Leon D ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

African American; Bcl 2; Bcl XL; Breast cancer; Caucasian; Health disparities; Insulin like growth factor II; Survivin

Indexed keywords

PROTEIN BCL 2; PROTEIN BCL X; SMALL INTERFERING RNA; SOMATOMEDIN B;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CAUCASIAN; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; CELL SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEALTH STATUS DISPARITIES; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 77949657070     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2009.12.002     Document Type: Article

References (28)

1. Surveillance, Epidemiology, and End Results program (SEER) SEER Stat Database: Mortality-All COD, Public-Use with State, Total U.S. for Expanded Races/Hispanics (1991-2001). National Cancer Institute, DC-CPS, Surveillance Research Program, Cancer Statistics Branch, 2004 (Released April). http://www.seer.cancer.gov.
2. Morrione A., Valentinis B., Xu S.-Q., Yumet G., Louvi A., Efstratiadis A., Baserga R. Insulin-like growth factor II stimulates cell proliferation through the insulin receptor. Proc. Natl. Acad. Sci. 1997, 94:3777-3782.
3. Sciacca L., Constantino A., Pandini G., Mineo R., Frasca F., Scalia P., Sbraccia P., Goldfine I.D., Vigneri R., Belfiore A. Insulin receptor activation by IGF-II in breast cancers: evidence for a new autocrine/paracrine mechanism. Oncogene 1999, 18:2471-2479.
4. Pravtcheva D.D., Wise T.L. Metastazing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J. Exp. Zool. 1998, 281:43-57.
5. Perdue J.F., LeBon T.R., Kato J., Hampton B., Fujita-Yamaguchi Y. Binding specificities and transducing function of the different molecular weight forms of IGF-II on IGF-IR. Endocrinology 1991, 129:3101-3108.
6. De León D.D., Wilson D.M., Powers M., Rosenfeld R.G. Effects of insulin-like growth factors and IGF receptor antibody on the proliferation of human breast cancer cells. Growth factors 1992, 6:327-336.
7. Kalla Singh S., Moretta D., Almaguel F., Wall N.R., De León M., De León D. Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells. Growth Factors 2007, 25:363-372.
8. L expression through different signaling pathways in breast cancer cells. Growth Factors 2008, 26:92-103.
9. Blanco-Aparicio C., Pequeño B., Moneo V., Romero L., Leal J.F., Velazco J., Fominaya J., Carnero A. Inhibition of PI3K synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria. Anti-cancer Drug. 2005, 16:977-987.
10. Vyas S., Asmerom Y., De León D.D. Resveratrol regulates IGF-II in breast cancer cells. Endocrinology 2005, 146:4224-4233.
11. Mu L., Katsaros D., Wiley A., Lu L., Rigault I.R., Smith S., Khubchandani S., Sochirca O., Arisio R., Yu H. Peptide concentrations and mRNA expression of IGF-I, IGF-II and IGFBP-3 in breast cancer and their associations with disease characteristics. Breast Cancer Res. Tr. 2009, 115:151-162.
12. Croci D.O., Cogno I.S., Vittar N.B., Salvatierra E., Trajtenberg F., Podhajeer O.L., Osinaga E., Rabinovich G.A., Rivorola V.A. Silencing survivin gene expression promotes apoptosis of human breast cancer cells through a caspase-independent pathway. J. Cell. Biochem. 2008, 105:381-390.
13. L in human breast cancer cells enhances organ-selective lymph node metastasis. Breast Cancer Res. Tr. 2004, 87:33-44.
14. Giodini A., Kallio M.J., Wall N.R., Gorbsky G.J., Tognin S., Marchisio P.C., Symons M., Altieri D.C. Regulation of microtubule stability and mitotic progression by survivin. Cancer Res. 2002, 62:2462-2467.
15. Hinnis A.R., Luckett J.C., Walker R.A. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Brit. J. Cancer 2007, 96:639-645.
16. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 2000, 6:127-134.
17. Olopade O.I., Adeyanju M.O., Safa A.R. Overexpression of Bcl-X protein in primary breast cancer is associated with high tumor grade and nodal metastases. Cancer J. Sci. Am. 1997, 3:230-237.
18. L mediated changes in metabolic pathways of breast cancer cells. Am. J. Pathol. 2005, 167:1125-1137.
19. Pietenpol J.A., Papadopoulos N., Markowitz S., Willson J.K., Kinzler K.W., Vogelstein B. Paradoxical inhibition of solid tumor cell growth by Bcl-2. Cancer Res. 1994, 54:3714-3717.
20. Callagy G.M., Pharoah P.D., Pinder S.E., Hsu F.D., Nielsen T.O., Ragaz J., Ellis I.O., Huntsman D., Caldas C. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham prognostic index. Clin. Cancer Res. 2006, 12:2468-2475.
21. L is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 2006, 6:213-217.
22. Li S.L., Goko H., Xu Z.D., Kimura G., Sun Y., Kawachi M.H., Wilson T.G., Wilczynski S., Fujita-Yamaguchi Y. Expression of insulin like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. Cell Tissue Res. 1998, 291:469-479.
23. Pedersen S.K., Christiansen J., Hansen T., Larsen M.R., Nielsen F.C. Human insulin-like growth factor II leader 2 mediates internal initiation of translation. Biochem J. 2002, 363:37-44.
24. Vikesaa J., Hansen J., Jonson L., Borup R., Wewer U.M., Christiansen J., Nielsen F.C. RNA-binding IMPs promote cell adhesion, and invadopodia formation. EMBO J. 2006, 25:1456-1468.
25. Hartmann L.C., Sellers T.A., Frost M.H., Lingle W.L., Degnim A.C., Ghosh K., Vierkant R.A., Maloney S.D., Pankratz V.S., Hillman D.W., Suman V.J., Johnson J., Blake C., Tlsty T., Vachom C.M., Melton L.J., Visscher D.W. Benign breast disease and the risk of breast cancer. New Engl. J. Med. 2005, 353:229-237.
26. Devedjian J.-C., George M., Casellas A., Pujol A., Visa J., Pelegrin M., Gros L., Bosch F. Transgenic mice overexpressing insulin-like growth factor II in β cells develop type 2 diabetes. J. Clin. Invest. 2000, 105:731-740.
27. Rose D.P., Haffner S.M., Baillargeon J. Adiposity, the metabolic syndrome, and breast cancer in African-American and White American women. Endocr. Rev. 2007, 28:763-777.
28. Buchanan C.M., Phillips A.R., Cooper G.J. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet β-cells and enhances insulin secretion. Biochem J. 2001, 360:431-439.